Lv4
740 积分 2025-08-04 加入
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
1个月前
已完结
The obesity–inflammation axis in psoriatic disease: mechanisms and therapeutic strategies
2个月前
已完结
Safety, pharmacokinetics and pharmacodynamics of HRS ‐7535, a novel oral small molecule glucagon‐like peptide‐1 receptor agonist, in healthy participants: A phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose, and food effect trial
2个月前
已完结
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial
3个月前
已完结
Impact of BRCA Mutation on Treatment Outcomes of Endocrine Therapy ± CDK4/6 Inhibitors in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor-2–Negative Breast Cancer: A Systematic Review and Meta-Analysis
3个月前
已关闭
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
4个月前
已完结
Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension
4个月前
已完结
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
7个月前
已完结
2023 International Rome consensus for the nomenclature of Sjögren disease
8个月前
已完结
More than a leaky gut: how gut priming shapes arthritis
8个月前
已完结
皖公网安备34019202002308
